Alzheimer?s disease: Updated multi-targets therapeutics are in clinical and in progress

被引：59
|
作者：
Sang, Zhipei [1 ,2 ]
Wang, Keren [3 ]
Dong, Jianghong [4 ]
Tang, Lei [1 ]
机构：
[1] Guizhou Med Univ, Guizhou Prov Engn Technol Res Ctr Chem Drug R&D, State Key Lab Funct & Applicat Med Plants, Guiyang 550004, Peoples R China
[2] Hainan Univ, Sch Pharmaceut Sci, Haikou 570228, Hainan, Peoples R China
[3] Nanyang Normal Univ, Coll Chem & Pharmaceut Engn, Nanyang 473061, Peoples R China
[4] Huanghuai Univ, Coll Chem & Pharmaceut Engn, Zhumadian 330004, Peoples R China
来源：
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2022年 / 238卷
关键词：
Alzheimer?s disease; Multi-target-directed ligands; ADME property; MULTITARGET-DIRECTED LIGANDS; POTENTIAL MULTIFUNCTIONAL AGENTS; AMYLOID-BETA AGGREGATION; HISTAMINE H3 RECEPTOR; MONOAMINE OXIDASE-B; BIOLOGICAL EVALUATION; BUTYRYLCHOLINESTERASE INHIBITORS; ACETYLCHOLINESTERASE INHIBITORS; NEUROPROTECTIVE PROPERTIES; CHOLINESTERASE-INHIBITORS;
D O I：
10.1016/j.ejmech.2022.114464
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Alzheimer's disease is a chronic and progressive brain neurodegenerative disease affecting over 30 million people globally. Currently, no effective treatment is available due to multiple factors involved in the progression of AD. Given that the numerous AD-related targets in the disease network, the multi-target-directed ligands (MTDLs) strategy are considered as the promising strategy to treat AD. Herein, the multi-target compounds with/ without ChEs are in clinical and in progress are reviewed. To further characterize the drug-likeness, and ADME properties are calculated using the Qikprop. This review will provide highlights for the treatment of AD.
引用
收藏
页数：38
相关论文
共 50 条
  • [1] Multifactorial Hypothesis and Multi-Targets for Alzheimer's Disease
    Gong, Cheng-Xin
    Liu, Fei
    Iqbal, Khalid
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2018, 64 : S107 - S117
  • [2] Multi-Targets: An Unconventional Drug Development Strategy for Alzheimer's Disease
    Gong, Cheng-Xin
    Dai, Chun-Ling
    Liu, Fei
    Iqbal, Khalid
    [J]. FRONTIERS IN AGING NEUROSCIENCE, 2022, 14
  • [3] Treatment of Alzheimer's disease front angles of multi-targets by using Chinese herb compounds
    Li, L.
    Zhang, L.
    Zhao, L.
    Wang, W.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 170 - 170
  • [4] Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease
    Sahoo, Atish Kumar
    Dandapat, Jagnehswar
    Dash, Umesh Chandra
    Kanhar, Satish
    [J]. JOURNAL OF ETHNOPHARMACOLOGY, 2018, 215 : 42 - 73
  • [5] Neuroprotective therapeutics for Alzheimer's disease: progress and prospects
    Palmer, Alan M.
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2011, 32 (03) : 141 - 147
  • [6] Progress and challenges in developing therapeutics for Alzheimer's disease
    Wolfe, Michael S.
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 246
  • [7] Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics
    Belaidi, Abdel A.
    Bush, Ashley I.
    [J]. JOURNAL OF NEUROCHEMISTRY, 2016, 139 : 179 - 197
  • [8] Molecular Targets in Alzheimer's Disease: From Pathogenesis to Therapeutics
    Cheng, Xuan
    Zhang, Lu
    Lian, Ya-Jun
    [J]. BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [9] Neuroinflammation in Alzheimer's Disease: Current Progress in Molecular Signaling and Therapeutics
    Thakur, Sujata
    Dhapola, Rishika
    Sarma, Phulen
    Medhi, Bikash
    Reddy, Dibbanti HariKrishna
    [J]. INFLAMMATION, 2023, 46 (01) : 1 - 17
  • [10] Neuroinflammation in Alzheimer’s Disease: Current Progress in Molecular Signaling and Therapeutics
    Sujata Thakur
    Rishika Dhapola
    Phulen Sarma
    Bikash Medhi
    Dibbanti HariKrishna Reddy
    [J]. Inflammation, 2023, 46 : 1 - 17
12345